← Leaderboards
Tracey Simon
Brigham And Women'S Hospital
$3,656,489
Attributed
$3,656,489
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,656,489 · 2
By mechanism
R01$2,604,074 · 1
K23$1,052,415 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Krista F Huybrechts$10,039,261
- Joshua K Lin$16,782,382
- Sebastian G. Schneeweiss$14,258,306
- Brian Thomas Bateman$6,450,805
- Zara R Cooper$5,346,007
Others in their field
Other Emerging Leaders on “Morbidity - Disease Rate”
- Stephen F Smagula · University Of Pittsburgh At Pittsburgh$5,369,879
- Karen Yazzie · Fort Belknap Indian Community$2,692,724
- Henning Tiemeier · University Of Chicago$2,503,974
- Molly Adrian · Seattle Children'S Hospital$2,302,897
- Shabbar I Ranapurwala · Univ Of North Carolina Chapel Hill$2,061,226
- Elizabeth Van Nostrand · University Of Pittsburgh At Pittsburgh$1,889,694
Research focus
Morbidity - Disease RateHigh DimensionalityDoseLiverPrevalenceAgedClinical TrialsDiagnosisFallsLinkMortalityPharmaceutical PreparationsAdultPreventionCirrhosisClinical CareCohortDatabasesAffectEpidemicHepaticAreaChemopreventionBiopsy
Grant awards (9)
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation$844,561
R01 · FY2025 · HL · contact PI
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation$870,427
R01 · FY2024 · HL · contact PI
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation$889,086
R01 · FY2023 · HL · contact PI
Aspirin and Novel Lipid Mediators in Nonalcoholic Fatty Liver Disease$199,383
K23 · FY2023 · DK · contact PI
Aspirin and Novel Lipid Mediators in Nonalcoholic Fatty Liver Disease$199,383
K23 · FY2022 · DK · contact PI
Aspirin and Novel Lipid Mediators in Nonalcoholic Fatty Liver Disease$54,000
K23 · FY2022 · DK · contact PI
Aspirin and Novel Lipid Mediators in Nonalcoholic Fatty Liver Disease$199,383
K23 · FY2021 · DK · contact PI
Aspirin and Novel Lipid Mediators in Nonalcoholic Fatty Liver Disease$199,383
K23 · FY2020 · DK · contact PI
Aspirin and Novel Lipid Mediators in Nonalcoholic Fatty Liver Disease$200,883
K23 · FY2019 · DK · contact PI